Lixte Biotechnology Holdings, Inc.
NASDAQ: LIXT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Geordan G. Pursglove
- Employees
- 2
- Headquarters
- Pasadena, United States
- IPO year
- 2007
- Market cap
- $79.7M
- Website
- https://lixte.com
Loading LIXT…
Loading profile data…Frequently asked questions about LIXT
What does Lixte Biotechnology Holdings, Inc. (LIXT) do?
Lixte Biotechnology Holdings, Inc. is a drug discovery company focused on developing new treatments. It employs biomarker technology to identify crucial enzyme targets associated with serious, widespread diseases, then designs innovative compounds to act upon these targets. The company's primary focus lies in protein phosphatase inhibitors, whic...
Where does LIXT trade?
Lixte Biotechnology Holdings, Inc. (LIXT) trades on the NASDAQ Capital Market.
What sector is LIXT in?
Lixte Biotechnology Holdings, Inc. (LIXT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lixte Biotechnology Holdings, Inc.?
Geordan G. Pursglove is the chief executive officer of Lixte Biotechnology Holdings, Inc. (LIXT).
Where is Lixte Biotechnology Holdings, Inc. headquartered?
Lixte Biotechnology Holdings, Inc. is headquartered in United States.
Does LIXT pay a dividend?
Lixte Biotechnology Holdings, Inc. (LIXT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LIXT go public?
Lixte Biotechnology Holdings, Inc. (LIXT) completed its initial public offering in 2007.